New potential therapies like MDMA will need more infrastructure beyond just buildings. The post Prepping the psychedelic industry for MDMA approval appeared...
The firm will now able to conduct research trials in the United States. The post Filament Health’s psychedelic drug candidate gains FDA nod appeared...
VANCOUVER, BC, Jan. 31, 2024 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage...
SAN FRANCISCO – Jaguar Health, Inc. (NASDAQ: JAGX) today announced that a preclinical study in mice initiated in Brazil by Magdalena Biosciences,...
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) — Huxley Health Inc. (“Huxley” or the “Company”) is pleased to provide you with a comprehensive corporate...
MindBio Therapeutics Corp. announced it is nearing the completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder....
The company also named several other new executives. The post Huxley Health finalizes Sintalica deal, names Bruce Linton chairman appeared first on Green...
Privately-owned psychedelics company Huxley Health Inc. has completed its acquisition of Canadian drug discovery company Sintalica and named Bruce Linton...
Psychedelic Invest publishes its annual psychedelics industry report summarizing all of the events of 2023.
The Psychedelic Education Market is Expanding Rapidly This rapid expansion is occurring in response to growth— both real and perceived- in the greater...